Sensei Biotherapeutics Inc

NASDAQ:SNSEUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.

Contact Information

Headquarters

1405 Research Blvd, Suite 125ROCKVILLE, MD, United States 20850

Phone

240-243-8000

Fax

302-531-3150

Executives

Independent Chairman of the Board

William Ringo

President, Chief Executive Officer, Director

John Celebi

Principal Financial Officer and Principal Accounting Officer

Josiah Craver

Chief Scientific Officer

Edward van Der Horst

Chief Business Officer

Stephanie Krebs